FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613(devimistat)

▴ FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613(devimistat)
CPI-613(devimistat) is indicated for the treatment of soft tissue sarcoma

Rafael Pharmaceuticals, Inc , a leader in the growing field of cancer metabolism-based therapeutics announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for CPI-613 (devimistat) for the treatment of soft tissue sarcoma.

Soft tissue sarcoma is a type of cancer that starts in the soft tissues of the body, such as fat, muscle, nerves, fibrous tissues, blood vessels or deep skin tissues. There are more than 50 different types of soft tissue sarcomas, and the clear cell is ranked among the rarest. Rafael’s clinical trial will focus on the treatment of relapsed or refractory clear cell sarcoma.

“There is a significant unmet need in treatment for soft tissue sarcoma,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. “When a disease is rare, it often does not receive the attention and focus necessary to develop effective treatments for it. We want to be a voice for those diagnosed with hard-to-treat cancers so that they know that they are not forgotten. We are focusing our attention on developing treatments for these cancers. In fact, Rafael is one of the only companies working on a treatment for clear cell sarcoma.”

This announcement comes on the heels of the Company’s most recent news around crossing the enrollment of 100 patients in its Phase 3 trial for relapsed or refractory acute myeloid leukaemia (AML).

About CPI-613 (devimistat)
CPI-613 (devimistat) is a first-in-class clinical lead compound of Rafael, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. Devimistat is designed to target the mitochondrial tricarboxylic acid (TCA) cycle, a process essential to tumor cell multiplication and survival, selectively in cancer cells. Devimistat substantially increases the sensitivity of cancer cells to a diverse range of chemotherapeutic agents. This synergy allows for potential combinations of devimistat with lower doses of these generally toxic drugs to be more effective with lower patient’s side effects. Combination with devimistat represents a diverse range of opportunities to substantially improve patient’s benefit in many different cancers. The U.S. Food and Drug Administration (FDA) has given Rafael approval to initiate pivotal Phase 3 clinical trials in pancreatic cancer (AVENGER 500) and acute myeloid leukemia (ARMADA 2000), and has designated devimistat as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome, peripheral T-cell lymphoma and Burkitt’s lymphoma. The EMA has granted orphan drug designation to devimistat for pancreatic cancer and acute myeloid leukaemia.

Tags : #RafaelPharmaceuticals #LatestSarcomaTreatment #Devimistat #LatestFDANewsOct31 #FDA #CancerTherapeutics

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Why Are Rare Disease Patients Paying a Fortune When Local Production Could Save Lives?November 07, 2024
Building Lips in the Lab: How Scientists Are Growing Lab Lips to Heal and RebuildNovember 07, 2024
National Cancer Awareness Day: How Small Changes Today Can Save Lives TomorrowNovember 07, 2024
Introducing an AI tool for accurate diagnosis of cholelithiasis on abdominal CT scansNovember 06, 2024
Nat Habit Unveils New Chapter of “Breathe Life Into Your Beauty” Campaign championed by Content Creators and the Launch of VeDHA, digital skin analysis toolNovember 06, 2024
High Level of Pollution Spikes Cardio and Respiratory Problems; Experts Call for Urgent Attention and Action to Mitigate the Risks November 06, 2024
HR leaders ready to shape India's future workforce - XLRI and Leadup Universe seminar in PuneNovember 05, 2024
Nestlé India and SM Sehgal Foundation celebrate 5 years of Project Vriddhi November 05, 2024
Why Tuberculosis Is Still the World’s Leading Killer in 2024 And How We’re Failing to Stop ItNovember 05, 2024
Crompton Launches the Nigella Pro Mixer Grinder to Revolutionize Kitchen ConvenienceNovember 05, 2024
Invisible Shadows: The Growing Crisis of Corneal Blindness in IndiaNovember 05, 2024
Thai AirAsia Entrusts Çelebi India with Ground Handling for New Hyderabad- Bangkok Flights, Signalling Further India Expansion November 05, 2024
Thai AirAsia Entrusts Çelebi India with Ground Handling for New Hyderabad- Bangkok Flights, Signalling Further India Expansion November 05, 2024
Discover 5 Platforms That Turn Your Pennies into PowerhousesNovember 04, 2024
Breathless in the Capital: Post-Diwali Smog Triggers Health Alarms in DelhiNovember 04, 2024
Is Your Diet Fuelling Your Disease? The Shocking Link Between Oil and Multiple SclerosisNovember 04, 2024
Unmasking the Danger Within: The Alarming Rise of Stomach Cancer in IndiaNovember 04, 2024
Hospital-acquired infections are fuelling antimicrobial resistance October 30, 2024
Transforming Patient Care: HealthTech Startups Making Waves in HealthcareOctober 30, 2024
Hospital-acquired infections are fuelling antimicrobial resistance October 30, 2024